Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306 / F. Pietrantonio, M.C. Garassino, V. Torri, F. De Braud. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 23:10(2012), pp. mds332.2771-mds332.2772. [10.1093/annonc/mds332]
Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306
F. Pietrantonio;F. De Braud
2012
File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
mds332.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
147.12 kB
Formato
Adobe PDF
|
147.12 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.